TWiV 1173: Holy Cow! Convergent evolution!

TWiV reviews nominees to head NIH, FDA, and CDC, cervical cancer decline following HPV vaccination, local dengue in Texas, human isolate of H5N1 virus is transmissible and virulent in animal models, and shared mechanisms of immune evasion among animal and bacterial viruses. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, Brianne Barker, and Jolene Ramsey… Continue reading TWiV 1173: Holy Cow! Convergent evolution!

The viral puzzle of why humans are susceptible to hepatitis B virus, but monkeys are not

Hepatitis B virus (HBV) has a narrow host range, mainly infecting hominoids. A new study reveals the structural differences in the liver cell receptor (NTCP) between humans and monkeys, explaining why HBV infects humans but not monkeys. This marks a significant medical breakthrough, by identifying new molecular targets for anti-HBV drug development for treating hepatitis… Continue reading The viral puzzle of why humans are susceptible to hepatitis B virus, but monkeys are not

Editors’ Picks, November 2024: Cervical Cancer in Native Americans, Nanovaccines, and More

The cover of Cancer Prevention Research was adopted from a figure in the study that showed the abundance of bacteria in the vaginal microbiome. As we head into the holiday season, Cancer Research Catalyst has tantalizing teasers in the form of science stocking stuffers straight from our November edition of Editors’ Picks. This month, the… Continue reading Editors’ Picks, November 2024: Cervical Cancer in Native Americans, Nanovaccines, and More

Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer

Purpose Recurrent or metastatic cervical cancer (r/m CC) presents limited treatment options for patients failed or progressed quickly following first-line therapy. This study investigated the potential of sintilimab with a prophylactic human papillomavirus (HPV) quadrivalent vaccine as a second-line treatment for r/m CC. Methods In this phase 2 clinical trial, patients with r/m CC previously… Continue reading Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer